Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 10/20 | 0.72 |
| ▸ | HTR1A | P08908 | 5/20 | 0.65 |
| ▸ | HTR2A | P28223 | 3/20 | 0.63 |
| ▸ | HTR1B | P28222 | 6/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630383 | 0.95 | HTR1D (0.76) | HTR1DHTR1AHTR2AHTR1BCYP1A2 | |
| SCHEMBL23069144 | 0.95 | HTR1D (0.76) | HTR1DHTR1AHTR2AHTR1BCYP1A2 | |
| SCHEMBL30630375 | 0.94 | HTR1D (0.77) | HTR1DHTR1AHTR2AHTR1BCYP1A2 | |
| SCHEMBL23083090 | 0.94 | HTR1D (0.77) | HTR1DHTR1AHTR2AHTR1BCYP1A2 | |
| SCHEMBL30630301 | 0.91 | HTR1B (0.67) | HTR1DHTR1AHTR2AHTR1BCYP1A2 | |
| SCHEMBL30630357 | 0.91 | HTR1D (0.77) | HTR1DHTR1AHTR2AHTR1BCYP1A2 | |
| SCHEMBL27085054 | 0.91 | HTR1B (0.67) | HTR1DHTR1AHTR2AHTR1BCYP1A2 | |
| SCHEMBL27084708 | 0.91 | HTR1D (0.77) | HTR1DHTR1AHTR2AHTR1BCYP1A2 | |
| SCHEMBL24243678 | 0.91 | HTR1D (0.59) | HTR1DHTR1AHTR2AHTR1BCYP1A2 | |
| SCHEMBL30630363 | 0.91 | HTR1D (0.59) | HTR1DHTR1AHTR2AHTR1BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| CN-117120415-A | Modified indole alkaloids for therapeutic use | 指南针探路者有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR1D 53/4885HTR1A 23/4885HTR2A 5/4885 |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR1D 53/4885HTR1A 23/4885HTR2A 5/4885 |
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | INMT, AANAT, HNMT | HTR1D 664/4885HTR1A 181/4885HTR2A 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.